Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Triazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | PTAFR | P25105 | 8/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | BRD4 | O60885 | 2/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triazolam SCHEMBL29382425 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL5142333 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29228 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29368430 | 1.00 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL27600059 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL9055695 | 0.99 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL3262516 | 0.93 | GABRA1 (0.86) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL13352295 | 0.91 | GABRA1 (0.83) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL28059256 | 0.89 | GABRA1 (0.79) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| SCHEMBL8274469 | 0.89 | GABRA1 (0.80) | GABRA1GABRA5GABRA2GABRA3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | claimed |
| EP-4687831-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4)-2.4-CHLORO-4-ETHYL-7. 3-FLUORO-3.5-METHOXY-3.2,5- DIOXO-1.4-(TRIFLUOROMETHYL)-3 .2H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-7.4-CARBOXAMIDE | Bayer Aktiengesellschaft (DE) | 2026-02-11 | — | — | EP | claimed |
| WO-2025027624-A1 | CYCLIC GLYCOLIPOPEPTIDE VACCINE ADJUVANTS AND THE PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGN. OF SOC. ACT (ACT XXI OF 1860) (IN) | 2025-02-06 | — | — | WO | claimed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | claimed |
| WO-2024200335-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32 H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-10-03 | — | — | WO | claimed |
| US-20240316019-A1 | METHODS OF PREVENTING SYMPTOMATIC ISCHEMIC STROKE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-26 | — | — | US | claimed |
| US-20240173310-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | claimed |
| US-20240174633-A1 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | claimed |
| EP-4304561-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | Bayer Aktiengesellschaft (DE) | 2024-01-17 | — | — | EP | claimed |
| EP-4304714-A1 | CRYSTALLINE FORMS OF (4S)-2 4-CHLORO-4-ETHYL-7 3-FLUORO-3 5-METHOXY-3 2,5-DIOXO-1 4-(TRIFLUOROMETHYL)-3 2H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-5 DIBENZENAHEPTAPHANE-7 4-CARBOXAMIDE | Bayer Aktiengesellschaft (DE) | 2024-01-17 | — | — | EP | claimed |
| WO-2022189278-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | WO | claimed |
| WO-2022189279-A1 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-5 DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | WO | claimed |
| WO-2022189280-A1 | SOLVATES OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32 H-6- AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | WO | claimed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | claimed |
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106403-A1 | NOVEL NRF2 ACTIVATOR AND USE THEREOF | 나손사이언스(주) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3580224-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11320441-B2 | Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2022-05-03 | — | — | US | disclosed |
| CN-113966508-A | Reconstructed segmented code and method of use | 可重构可视代码技术公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174633-A1 | CRYSTALLINE FORMS OF (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUORO-METHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | CYP4F2, CYP4F8, CYP4F12 | GABRA1 2335/4885GABRA5 2250/4885GABRA2 2435/4885 |
| US-20240316019-A1 | METHODS OF PREVENTING SYMPTOMATIC ISCHEMIC STROKE | FABP7, FABP3, APOB | GABRA1 931/4885GABRA5 803/4885GABRA2 737/4885 |
| US-20260132133-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KRAS, HRAS, BCL6 | GABRA1 1245/4885GABRA5 1869/4885GABRA2 1800/4885 |
| US-20240173310-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | CYP4F8, CYP4F2, CYP2F1 | GABRA1 1190/4885GABRA5 1320/4885GABRA2 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.